☰

Enrico Mihich, MD - Publications

Affiliations: 
State University of New York, Buffalo, Buffalo, NY, United States 
 1957- Roswell Park Cancer Institute, Buffalo, NY, United States 
Area:
Drug development; antineoplastic therapy
Tree Info Grants Similar researchers PubMed Report error

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Kaelin W, Livingston D, Loda M, Vousden K, Mihich E. Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. Cancer Research. 73: 6124-7. PMID 24097824 DOI: 10.1158/0008-5472.Can-13-2445  0.313
2013 Marais R, Sellers W, Livingston D, Mihich E. Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. Cancer Research. 73: 1046-9. PMID 23222297 DOI: 10.1158/0008-5472.Can-12-3236  0.341
2012 Friedl P, Hubbell J, Livingston D, Mihich E. Twenty-third annual Pezcoller Symposium: engineering influences in cancer research. Cancer Research. 72: 841-4. PMID 22237623 DOI: 10.1158/0008-5472.Can-11-3080  0.371
2011 Zaenker KS, Mihich E, Liu E. Personalized Cancer Medicine 2011: Toward Individualized Cancer Treatments. XV International Fritz Bender Symposium Held on February 21 to 23, 2011 at Matrix, Biopolis, Singapore. Translational Oncology. 4: 199-202. PMID 21804914 DOI: 10.1593/Tlo.11142  0.317
2006 Weinberg R, Mihich E. Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions. Cancer Research. 66: 11550-3. PMID 17158190 DOI: 10.1158/0008-5472.Can-06-3149  0.307
2006 Gerhauser C, Bartsch H, Crowell J, De Flora S, D'Incalci M, Dittrich C, Frank N, Mihich E, Steffen C, Tortora G, Gescher A. Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. European Journal of Cancer (Oxford, England : 1990). 42: 1338-43. PMID 16730975 DOI: 10.1016/J.Ejca.2006.02.007  0.307
2006 Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Research. 66: 5419-26. PMID 16707470 DOI: 10.1158/0008-5472.Can-05-3963  0.376
2004 Mihich E, Jaenisch R. Sixteenth Annual Pezcoller Symposium: stem cells and epigenesis in cancer. Cancer Research. 64: 8474-7. PMID 15548721 DOI: 10.1158/0008-5472.Can-04-2625  0.334
2004 Mihich E, Kaelin W. Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. Cancer Research. 64: 2929-33. PMID 15087414 DOI: 10.1158/0008-5472.Can-03-2995  0.325
2003 Mihich E. Cellular immunity for cancer chemoimmunotherapy--an overview. Cancer Immunology, Immunotherapy : Cii. 52: 661-2. PMID 12942199 DOI: 10.1007/S00262-003-0423-6  0.328
2003 Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunology, Immunotherapy : Cii. 52: 463-72. PMID 12698271 DOI: 10.1007/S00262-003-0391-X  0.333
2001 Berleth ES, Masso-Welch PA, Kazim LA, Ip MM, Mihich E, Ehrke MJ. Expression, tissue distribution, and cellular localization of the antiapoptotic TIP-B1 protein. Journal of Leukocyte Biology. 69: 995-1005. PMID 11404387 DOI: 10.1189/Jlb.69.6.995  0.319
2001 Mihich E, Berleth E, Henn A, Ehrke M. Modulation of tumor necrosis factor (TNFα) in cancer therapeutics European Journal of Cancer. 37: S148. DOI: 10.1016/S0959-8049(01)81037-6  0.336
2000 Mihich E. On The Immunomodulating Effects of Anti-Cancer Drugs and Their Therapeutic Exploitation Japanese Journal of Clinical Oncology. 30: 469-471. PMID 11155915 DOI: 10.1093/Jjco/Hyd127  0.308
2000 Mihich E, Ehrke MJ. Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. International Journal of Immunopharmacology. 22: 1077-81. PMID 11137614 DOI: 10.1016/S0192-0561(00)00072-2  0.348
2000 Ehrke MJ, Verstovsek S, Maccubbin DL, Ujházy P, Zaleskis G, Berleth E, Mihich E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. International Journal of Cancer. 87: 101-9. PMID 10861459 DOI: 10.1002/1097-0215(20000701)87:1<101::Aid-Ijc15>3.0.Co;2-B  0.333
1998 Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Meer JM, Mihich E. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. International Journal of Cancer. 76: 579-86. PMID 9590137 DOI: 10.1002/(Sici)1097-0215(19980518)76:4<579::Aid-Ijc22>3.0.Co;2-1  0.347
1998 Ehrke MJ, Verstovsek S, Ujházy P, Meer JM, Eppolito C, Maccubbin DL, Mihich E. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunology, Immunotherapy : Cii. 45: 287-98. PMID 9490198 DOI: 10.1007/S002620050445  0.343
1996 Ujházy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E. Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. International Journal of Cancer. 68: 493-500. PMID 8945621 DOI: 10.1002/(Sici)1097-0215(19961115)68:4<493::Aid-Ijc15>3.0.Co;2-6  0.301
1996 Ehrke MJ, Verstovsek S, Zaleskis G, Ho RL, Ujházy P, Maccubbin DL, Mihich E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunology, Immunotherapy : Cii. 42: 221-30. PMID 8665569 DOI: 10.1007/S002620050274  0.318
1995 Ehrke MJ, Verstovsek S, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Mihich E. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. International Journal of Cancer. 63: 463-71. PMID 7591249 DOI: 10.1002/Ijc.2910630327  0.33
1994 Tzai TS, Huben RP, Zaleskis G, Berleth ES, Ehrke MJ, Mihich E. Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer. The Journal of Urology. 151: 1680-6. PMID 8189597 DOI: 10.1016/S0022-5347(17)35344-2  0.367
1993 Verstovsek S, Maccubbin DL, Ehrke MJ, Mihich E. Polymyxin B-mediated lysis of tumor cells. International Archives of Allergy and Immunology. 100: 47-52. PMID 8428163 DOI: 10.1159/000236386  0.342
1988 Maccubbin DL, Whitman JA, Taniguchi N, Mace KF, Ehrke MJ, Mihich E. Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin. International Journal of Immunopharmacology. 10: 317-23. PMID 3263335 DOI: 10.1016/0192-0561(88)90064-1  0.359
1986 Ryoyama K, Ryoyama C, Mihich E. Inhibition of suppressor cell generation by mouse serum in culture International Journal of Immunopharmacology. 8: 23-32. PMID 2937749 DOI: 10.1016/0192-0561(86)90069-X  0.343
1985 Mihich E. Biological response modifiers: their potential and limitations in cancer therapeutics. Cancer Investigation. 3: 71-83. PMID 2578860 DOI: 10.3109/07357908509040609  0.323
1985 Jane Ehrke M, Mihich E. Effects of anticancer agents on immune responses Trends in Pharmacological Sciences. 6: 412-417. DOI: 10.1016/0165-6147(85)90193-2  0.327
1984 Ryoyama K, Ehrke MJ, Mihich E. Induction of suppressor T cells in culture--II. Modification by adriamycin. International Journal of Immunopharmacology. 6: 521-7. PMID 6238914 DOI: 10.1016/0192-0561(84)90091-2  0.376
1984 Ryoyama K, Ryoyama C, Ehrke MJ, Mihich E. Induction of suppressor T cells in culture--I. Cell-cell interactions. International Journal of Immunopharmacology. 6: 509-20. PMID 6238913 DOI: 10.1016/0192-0561(84)90090-0  0.366
1983 Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: dependence upon time of administration. International Journal of Immunopharmacology. 5: 43-8. PMID 6404846 DOI: 10.1016/0192-0561(83)90070-X  0.359
1983 Schlaefli E, Ehrke MJ, Mihich E. The effects of dichloro-trans-dihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology. 6: 107-22. PMID 6224759 DOI: 10.1016/0162-3109(83)90004-8  0.397
1983 Ehrke MJ, Reino JM, Eppolito C, Mihich E. The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. International Journal of Immunopharmacology. 5: 35-42. PMID 6220984 DOI: 10.1016/0192-0561(83)90069-3  0.332
1983 Leung KH, Ehrke MJ, Mihich E. Modification by biological products of the generation of suppressor cells in culture. Immunopharmacology. 5: 221-37. PMID 6219969 DOI: 10.1016/0162-3109(83)90029-2  0.359
1982 Cohen SA, Ehrke MJ, Ryoyama K, Mihich E. Augmentation of the phagocytic activity of murine spleen cell populations induced by Adriamycin. Immunopharmacology. 5: 75-84. PMID 7129860 DOI: 10.1016/0162-3109(82)90038-8  0.357
1982 Leung KH, Ehrke MJ, Bercsenyi K, Mihich E. Human prealbumin fraction: effects on cell-mediated immunity and tumor rejection. Immunopharmacology. 4: 55-67. PMID 7061225 DOI: 10.1016/0162-3109(82)90025-X  0.397
1982 Bogyo D, Ehrke MJ, Mihich E. Reversal by citrovorum factor of methotrexate-induced suppression of cell-mediated and humoral immune response in mouse model systems. Biochemical Pharmacology. 31: 1387-92. PMID 6980004 DOI: 10.1016/0006-2952(82)90033-8  0.334
1982 Leung KH, Mihich E. Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. International Journal of Immunopharmacology. 4: 205-17. PMID 6809648 DOI: 10.1016/0192-0561(82)90050-9  0.376
1982 Leung KH, Ehrke MJ, Mihich E. Modulation of the development of cell-mediated immunity: possible role of the products of the cyclo-oxygenase and the lipoxygenase pathways of arachidonic acid metabolism. International Journal of Immunopharmacology. 4: 195-204. PMID 6809647 DOI: 10.1016/0192-0561(82)90049-2  0.312
1982 Ryoyama K, Mace K, Ehrke MJ, Mihich E. The differential sensitivity of T cell immune functions to vincristine and vinblastine. International Journal of Immunopharmacology. 4: 187-93. PMID 6213573 DOI: 10.1016/0192-0561(82)90048-0  0.389
1980 Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature. 288: 597-600. PMID 7003398 DOI: 10.1038/288597A0  0.34
1980 Leung KH, Mihich E. Modulation of cell-mediated immunity by inhibitors of prostaglandin syntheses International Journal of Immunopharmacology. 2: 244-245. DOI: 10.1016/0192-0561(80)90221-0  0.313
1977 Bennett J, Ehrke J, Dave C, Mihich E. Selective effects of methylglyoxal-bis-(guanylhydrazone) on the development of antibody-forming cells in mice. Biochemical Pharmacology. 26: 723-8. PMID 856204 DOI: 10.1016/0006-2952(77)90215-5  0.363
1977 Medzihradsky J, Ehrke J, Mihich E. Time limitations in the reversal by citrovorum factor of methotrexate-induced immunosuppression in mice. Biochemical Pharmacology. 26: 203-206. PMID 300243 DOI: 10.1016/0006-2952(77)90303-3  0.335
1975 Orsini FR, Mihich E. Bone marrow determination of complement dependent and complement independent cellular cytotoxicity Cellular Immunology. 18: 424-434. PMID 1095218 DOI: 10.1016/0008-8749(75)90070-2  0.307
1973 Mawas C, Carey T, Mihich E. Study of the immune responses to nucleated cells. I. In vitro functional evaluation of the immune effectors responsible for complement-dependent cellular cytotoxicity Cellular Immunology. 6: 243-260. PMID 4540377 DOI: 10.1016/0008-8749(73)90025-7  0.348
Show low-probability matches.